

Executive Officer Notice:

Elimination of the Facilitated Access to HIV/AIDS Products Currently Listed in Part VI-A of the Ontario Drug Benefit Formulary/CDI

Effective May 31, 2024

This is an update to an earlier EO Notice dated February 28, 2024 regarding an interim extension of the facilitated access to HIV/AIDS (HIV FA) products currently listed in Part VI-A of the Ontario Drug Benefit Formulary/CDI (the “Formulary”).

For HIV/AIDS products currently listed in Part VI-A of the Formulary (i.e., under HIV FA):

Effective May 31, 2024, the ministry will be eliminating the HIV FA mechanism under the Ontario Drug Benefit (ODB) program for the products set out in the following table:

Generic Name and strength	Brand Name	DIN/NPN	Effective May 31, 2024:
Doxycycline 100mg Cap	Apo-Doxy	00740713	Funding will be provided on a case-by-case basis through the Exceptional Access Program (EAP) for eligible ODB program recipients who are unable to tolerate the tablet formulations of doxycycline which are listed as General Benefits on the Formulary.
	Teva-Doxycycline	00725250	
Paromomycin 250mg Cap	Humatin	02078759	Funding will be provided on a case-by-case basis through the EAP for eligible ODB program recipients. Note: Recommended for the treatment of cryptosporidium. Therapy should be

			discontinued if no benefits are observed after a three-week trial.
Nutrition Products	Funded nutrition products and their PIN/NPNs are listed in Part IX-A of the Formulary for eligible ODB program recipients.		The nutrition products will be removed from Part VI-A of the Formulary. The nutrition products will continue to be funded under the eligibility criteria outlined in Part IX-A of the Formulary for eligible ODB program recipients.
Pneumococcal Vaccine Inj-1 Dose Pk	Pneumovax 23	00431648	Pneumococcal vaccine will be removed from Part VI-A of the Formulary and will no longer be funded under the ODB program. Note: Pneumococcal vaccine is a publicly funded vaccine administered through Public Health Ontario. For more information, please contact your local Public Health Unit. You can use the Public Health Locator to see which unit is yours.
Potassium Chloride 8meq LA Tab and SR Cap	Apo-K	00602884	Potassium Chloride will be removed from Part VI-A of the Formulary and will no longer be funded under the ODB program.
	Micro-K Extencaps	02042304	

In the case of drug products eligible for funding under the EAP, an authorized prescriber, as defined in the *Ontario Drug Benefit Act*, must submit a request for funding to the ministry for review. The request must include relevant medical information about the ODB program recipient to whom the funding request relates, and any other information required to be submitted in a request for funding for a particular drug product. More information about the EAP and a direct link to the EAP application form can be found on the ministry’s website at: [Exceptional Access Program \(EAP\)](#).

Certain nutrition products are designated as listed substances on the Formulary and reimbursed for ODB program recipients in defined circumstances under Part IX-A of the Formulary. For ODB program recipients who meet the eligibility criteria in Part IX-A of the Formulary, each claim for reimbursement must be supported by a valid and fully completed Nutrition Product Form. The Nutrition Product form (which includes the eligibility criteria) can be accessed from the ministry’s website at: [Nutrition Product Form](#). Please refer to Part IX-A of the [Formulary](#) for more information.

Effective May 31, 2024, the existing HIV FA Physician List will no longer be in use and physician enrolment for HIV FA through the EAP will no longer be required.

Additional Information:

For pharmacies:

For billing inquiries, please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282

All other inquiries regarding the HIV FA mechanism under the ODB program should be directed to DrugProgramsDelivery@ontario.ca.